alpha antitrypsin deficiency epidemiology forecast report
DelveInsight’s ‘Alpha Antitrypsin Deficiency - Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Alpha Antitrypsin Deficiency in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017–2034
Alpha Antitrypsin Deficiency Disease Understanding
Alpha Antitrypsin Deficiency (AATD) occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. AAT protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.
Alpha Antitrypsin Deficiency Epidemiology
The Alpha Antitrypsin Deficiency epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. The epidemiology data for Alpha Antitrypsin Deficiency are studied through all possible division to give a better understanding about the Disease scenario in 6MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Alpha Antitrypsin Deficiency Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017–2034.
The DelveInsight report also provides the epidemiology trends observed in the 6MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total number of prevalent cases of Alpha Antitrypsin Deficiency in 6MM was found to be 175,009, in the year 2017.
Report Scope
• The report covers detailed overview of Alpha Antitrypsin Deficiency explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Alpha Antitrypsin Deficiency in 6 major markets covering the United States and EU5 (Germany, Spain, France, Italy, UK).
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 6MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD in 6MM
Key strengths
• 11 Year Forecast of Alpha Antitrypsin Deficiency epidemiology
• 6MM Coverage
• Total Prevalent Cases of AATDs
• Prevalent Cases according to segmentation: (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD)
Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
1 Key Insights
2 Executive Summary of Alpha Antitrypsin Deficiency
3 SWOT Analysis for Alpha Antitrypsin Deficiency
4 Patient Share of Alpha Antitrypsin Deficiency at a Glance
4.1 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2017
4.2 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2030
5 Alpha Antitrypsin Deficiency Market Overview at a Glance
5.1 Diagnosed Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2017
5.2 Diagnosed Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2030
6 Disease Background and Overview
6.1 Introduction
6.2 Symptoms
6.3 Etiology
6.4 Risk Factors
6.5 Genetic Inheritance of AAT Deficiency
6.6 Clinical Manifestations
6.7 Pathophysiology
6.8 Biomarkers
6.9 Diagnosis
6.1 Diagnostic Delay
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM
8 Country-wise Epidemiology of Alpha-1-Antitrypsin Deficiency
8.1 Assumptions and Rationale: 6MM
8.2 United States
8.2.1 Prevalence of Symptomatic AATD in the United States
8.2.2 Diagnosed population of AATD in the United States
8.2.3 Genotype of AATD Diagnosed patients in the United States
8.2.4 Comorbidity associated with AATD in the United States
8.3 EU5
8.3.1 Germany
8.3.1.1 Prevalence of Symptomatic AATD in Germany
8.3.1.2 Diagnosed population of AATD in Germany
8.3.1.3 Genotype of AATD Diagnosed patients in Germany
8.3.1.4 Comorbidity associated with AATD in Germany
8.3.2 France
8.3.2.1 Prevalence of Symptomatic AATD in France
8.3.2.2 Diagnosed population of AATD in France
8.3.2.3 Genotype of AATD Diagnosed patients in France
8.3.2.4 Comorbidity associated with AATD in France
8.3.3 Italy
8.3.3.1 Prevalence of Symptomatic AATD in Italy
8.3.3.2 Diagnosed population of AATD in Italy
8.3.3.3 Genotype of AATD Diagnosed patients in Italy
8.3.3.4 Comorbidity associated with AATD in Italy
8.3.4 Spain
8.3.4.1 Prevalence of Symptomatic AATD in Spain
8.3.4.2 Diagnosed population of AATD in Spain
8.3.4.3 Genotype of AATD Diagnosed patients in Spain
8.3.4.4 Comorbidity associated with AATD in Spain
8.3.5 United Kingdom
8.3.5.1 Prevalence of Symptomatic AATD in the United Kingdom
8.3.5.2 Diagnosed population of AATD in the United Kingdom
8.3.5.3 Genotype of AATD Diagnosed patients in the United Kingdom
8.3.5.4 Comorbidity associated with AATD in the United Kingdom
9 Treatment
9.1 Current therapies
9.1.1 Augmentation Therapy
9.1.2 Gene Therapy strategies
9.1.3 Lifestyle Changes
9.1.4 Novel therapeutics
10 Treatment Algorithm
10.1 Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
10.2 Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease
11 Unmet Needs
12 Organizations contributing toward Alpha Antitrypsin Deficiency
13 Case Reports
13.1 An unusual case of alpha-1-antitrypsin deficiency: SZ/Z
13.2 The Importance of Early Identification of Alpha-1 Antitrypsin Deficiency
13.3 A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis
14 Appendix
14.1 Bibliography
14.2 Report Methodology
15 DelveInsight Capabilities
16 Disclaimer
17 About DelveInsight
List of Tables:
Table 1: Summary of Alpha-1 Antitrypsin Deficiency (AATD) Epidemiology, and Key Events (2017–2030)
Table 2: Diagnostic Delay Interval for AATD
Table 3: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2017–2030)
Table 4: Prevalence of Symptomatic AATD in the United States (2017–2030)
Table 5: Diagnosed population of AATD in the United States (2017–2030)
Table 6: Genotype of AATD Diagnosed patients in the United States (2017–2030)
Table 7: Comorbidity associated with AATD in the United States (2017–2030)
Table 8: Prevalence of Symptomatic AATD in Germany (2017–2030)
Table 9: Diagnosed population of AATD in Germany (2017–2030)
Table 10: Genotype of AATD Diagnosed patients in Germany (2017–2030)
Table 11: Comorbidity associated with AATD in Germany (2017–2030)
Table 12: Prevalence of Symptomatic AATD in France (2017–2030)
Table 13: Diagnosed population of AATD in France (2017–2030)
Table 14: Genotype of AATD Diagnosed patients in France (2017–2030)
Table 15: Comorbidity associated with AATD in France (2017–2030)
Table 16: Prevalence of Symptomatic AATD in Italy (2017–2030)
Table 17: Diagnosed population of AATD in Italy (2017–2030)
Table 18: Genotype of AATD Diagnosed patients in Italy (2017–2030)
Table 19: Comorbidity associated with AATD in Italy (2017–2030)
Table 20: Prevalence of Symptomatic AATD in Spain (2017–2030)
Table 21: Diagnosed population of AATD in Spain (2017–2030)
Table 22: Genotype of AATD Diagnosed patients in Spain (2017–2030)
Table 23: Comorbidity associated with AATD in Spain (2017–2030)
Table 24: Prevalence of Symptomatic AATD in The United Kingdom (2017–2030)
Table 25: Diagnosed population of AATD in The United Kingdom (2017–2030)
Table 26: Genotype of AATD Diagnosed patients in The United Kingdom (2017–2030)
Table 27: Comorbidity associated with AATD in The United Kingdom (2017–2030)
Table 28: Organizations contributing toward Alpha-Antitrypsin Deficiency
List of Figures:
FIGURE 1: SWOT ANALYSIS
FIGURE 2: HISTORICAL OVERVIEW OF AATD DEVELOPMENT
FIGURE 3: SYMPTOMS ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY
FIGURE 4: RISK FACTORS FOR AATD
FIGURE 5: INHERITANCE OF AATD
FIGURE 6: INHERITANCE PATTERN OF AATD
FIGURE 7: ALPHA-1 ANTITRYPSIN BINDS AND INACTIVATES NEUTROPHIL ELASTASE.
FIGURE 8: PATHOGENESIS OF ALPHA ANTITRYPSIN DEFICIENCY
FIGURE 9: DIAGNOSTIC ALGORITHM OF ALPHA ANTITRYPSIN DEFICIENCY
FIGURE 10: ATS/ERS DIAGNOSTIC RECOMMENDATIONS FOR ALPHA ANTITRYPSIN DEFICIENCY
FIGURE 11: ATS/ERS RECOMMENDATIONS (TO BE DISCUSSED) FOR ALPHA ANTITRYPSIN DEFICIENCY
FIGURE 12: ATS/ERS DIAGNOSTIC RECOMMENDATIONS (NOT RECOMMENDED) FOR ALPHA ANTITRYPSIN DEFICIENCY
FIGURE 13: DIAGNOSTIC AND MONITORING METHODS FOR ALPHA ANTITRYPSIN DEFICIENCY
FIGURE 14: TOTAL PREVALENT POPULATION OF ALPHA-1-ANTITRYPSIN DEFICIENCY IN 6 MM (2017–2030)
FIGURE 15: PREVALENCE OF SYMPTOMATIC AATD IN THE UNITED STATES (2017–2030)
FIGURE 16: DIAGNOSED POPULATION OF AATD IN THE UNITED STATES (2017–2030)
FIGURE 17: GENOTYPE OF AATD DIAGNOSED PATIENTS IN THE UNITED STATES (2017–2030)
FIGURE 18: COMORBIDITY ASSOCIATED WITH AATD IN THE UNITED STATES (2017–2030)
FIGURE 19: PREVALENCE OF SYMPTOMATIC AATD IN GERMANY (2017–2030)
FIGURE 20: DIAGNOSED POPULATION OF AATD IN GERMANY (2017–2030)
FIGURE 21: GENOTYPE OF AATD DIAGNOSED PATIENTS IN GERMANY (2017–2030)
FIGURE 22: COMORBIDITY ASSOCIATED WITH AATD IN GERMANY (2017–2030)
FIGURE 23: PREVALENCE OF SYMPTOMATIC AATD IN FRANCE (2017–2030)
FIGURE 24: DIAGNOSED POPULATION OF AATD IN FRANCE (2017–2030)
FIGURE 25: GENOTYPE OF AATD DIAGNOSED PATIENTS IN FRANCE (2017–2030)
FIGURE 26: COMORBIDITY ASSOCIATED WITH AATD IN FRANCE (2017–2030)
FIGURE 27: PREVALENCE OF SYMPTOMATIC AATD IN ITALY (2017–2030)
FIGURE 28: DIAGNOSED POPULATION OF AATD IN ITALY (2017–2030)
FIGURE 29: GENOTYPE OF AATD DIAGNOSED PATIENTS IN ITALY (2017–2030)
FIGURE 30: COMORBIDITY ASSOCIATED WITH AATD IN ITALY (2017–2030)
FIGURE 31: PREVALENCE OF SYMPTOMATIC AATD IN SPAIN (2017–2030)
FIGURE 32: DIAGNOSED POPULATION OF AATD IN SPAIN (2017–2030)
FIGURE 33: GENOTYPE OF AATD DIAGNOSED PATIENTS IN SPAIN (2017–2030)
FIGURE 34: COMORBIDITY ASSOCIATED WITH AATD IN SPAIN (2017–2030)
FIGURE 35: PREVALENCE OF SYMPTOMATIC AATD IN THE UNITED KINGDOM (2017–2030)
FIGURE 36: DIAGNOSED POPULATION OF AATD IN THE UNITED KINGDOM (2017–2030)
FIGURE 37: GENOTYPE OF AATD DIAGNOSED PATIENTS IN THE UNITED KINGDOM (2017–2030)
FIGURE 38: COMORBIDITY ASSOCIATED WITH AATD IN THE UNITED KINGDOM (2017–2030)
FIGURE 39: TREATMENT RECOMMENDATIONS FOR AATD
FIGURE 40: AVAILABLE THERAPEUTICS OF ALPHA ANTITRYPSIN DEFICIENCY
FIGURE 41: STRATEGIES FOR DELIVERY OF ENGINEERED NUCLEASES: A) EX-VIVO ; B) IN VIVO
FIGURE 42:GENOME EDITING WITH ENGINEERED NUCLEASES
FIGURE 43: TREATMENT ALGORITHM OF ALPHA ANTITRYPSIN DEFICIENCY
FIGURE 44: ALGORITHM FOR MANAGEMENT OF ALPHA ANTITRYPSIN DEFICIENCY WITH LUNG DISEASE
FIGURE 45: ALGORITHM FOR MANAGEMENT OF ALPHA ANTITRYPSIN DEFICIENCY WITH LUNG DISEASE
FIGURE 46: CURRENT UNMET NEEDS
